In today’s briefing:
- FnGuide Top 10 Rebalancing on June 10: More Substantial Flow Impact than Last Time
- Smartkarma Corporate Webinar | Hyphens Pharma: Deepening Presence in ASEAN
- Dr Reddys Labs: Stable Results Despite Industry Headwinds; Maintain BUY
- Gland Pharma Ltd: Strong Growth Across Geographies to Drive Profitability
FnGuide Top 10 Rebalancing on June 10: More Substantial Flow Impact than Last Time
- Celltrion Inc (068270 KS)’s deletion seems pretty much a foregone conclusion as its average float-adjusted market cap on May 3-19 is way below the next one in line.
- Shinhan Financial (055550 KS) is the one to replace Celltrion based on the numbers so far. There is close to a ₩1T gap with the next one, POSCO (005490 KS).
- In this rebalancing, the flow impact of the addition/deletion is even more significant. So, their share price fluctuations on June 10 will likely be more substantial than last time.
Smartkarma Corporate Webinar | Hyphens Pharma: Deepening Presence in ASEAN
For our next Corporate Webinar, we are glad to welcome Hyphens Pharma International (HYP SP) Chairman and CEO, Mr. Lim See Wah.
In the upcoming webinar, Mr Lim will share a short company presentation, after which he will engage in a fireside chat with Smartkarma Analyst Tina Banerjee. A live Q&A session will follow.
The Corporate Webinar will be hosted on Tuesday, 7 June 2022, 17:00 SGT.
Hyphens Pharma International Limited and its subsidiaries (the “Group”) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia, and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, Oman, South Korea, and Sri Lanka.
Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development, and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets, and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online e-pharmacy for doctors to prescribe and have medications delivered to their patients’ homes.
Corporate Webinars by Smartkarma Corporate Solutions feature discussions with IROs and Executives, discussing their companies, the challenges they face, and the opportunities in their sectors and markets.
Dr Reddys Labs: Stable Results Despite Industry Headwinds; Maintain BUY
- Dr Reddy Q4FY22 reported revenue growth of 14.8% YoY (vs. our expectations of 8.0% YoY), led by strong performance in geographies such as the US, India, and Emerging Markets.
- The company is building a global pipeline of biosimilars, developments of NCE for Immuno-oncology, and building up a Neutraceuticals portfolio, vaccines, CDMO, and digital healthcare platforms
- However, high inflation could decrease margins prompting us to reduce TP to Rs 4,500/share.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Gland Pharma Ltd: Strong Growth Across Geographies to Drive Profitability
- Gland Pharma reported a good set of numbers with revenue for the Q4FY22 growing by 24.3% on a YoY basis.
- We believe stock trades at rich valuations of PE of 36.2x and 30.4x for FY23E and FY24E respectively
- We, therefore, recommend a HOLD rating on the stock with a target price of Rs 3,300/share.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.
Before it’s here, it’s on Smartkarma
